Capitalizing on the inherent biodistribution of senescent RBCs into the liver and spleen, scientists at ERYTECH were the first to highlight the potential of antigen-loaded RBCs to modulate immune function by demonstrating both the induction of protein-specific tolerance, and the generation of antigen-specific immune response and subsequent tumor growth control in vivo (Cremel et al., Int J Pharm 2015; Banz et al., J Immunother 2012).
In June 2019, we entered into a partnership with SQZ Biotech to advance novel immune modulating RBC-based therapeutic candidates which enables SQZ to combine its Cell Squeeze® cell engineering platform with Erytech’s significant IP and knowhow related to RBC-based therapeutics to develop novel immune modulating therapeutics addressing multiple indications.